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ABSTRACT 
 
Normal and neoplastic human mammary gland cells are targets 
for the proliferative action of prolactin. These cells also 
synthesize prolactin, thereby inducing an autocrine/paracrine 
proliferative loop. 
We present the first extensive analysis of the transcriptional 
regulation of the human prolactin gene (hPRL) in human mammary 
tumor cells, SK-BR-3. We show that the pituitary promoter is 
functional in these cells in the absence of the pituitary-
specific factor Pit-1. Expression of exogenous Pit-1 or EGF 
treatment stimulates the transfected hPRL pituitary promoter and 
the endogenous hPRL expression. EGF stimulation is mediated by 
increased synthesis of c-fos and c-jun, resulting in AP-1 binding 
to the proximal hPRL pituitary promoter. This regulation involves 
the EGF receptor, possibly ErbB2 that is highly expressed in SK-
BR-3 cells, and a PI3K/JNK pathway. 
The stimulation of hPRL gene transcription by EGF in mammary 
cells may include hPRL in a complex regulatory network 
controlling growth of human mammary cells. 
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INTRODUCTION 
 
Prolactin (PRL) is a polypeptide hormone mostly produced by 
the adeno-pituitary gland where its expression is modulated by 
numerous extracellular signals, e.g. TRH, EGF, thyroid hormones, 
glucocorticoids, estrogens and by second messengers Ca2+ and cAMP 
(Peers et al., 1990, 1991; Berwaer et al., 1991; 1993; Hoggard et 
al., 1991; Nalda et al., 1997; Pernasetti et al., 1997; Van De 
Weerdt et al., 2000; reviewed in Muller et al., 1998). It 
displays many biological activities triggered through binding to 
its specific transmembrane receptor (PRLR). In mammals, PRL 
mainly promotes growth and development of the mammary gland, as 
well as milk production and secretion (Shiu et al., 1987). PRL is 
also involved in human mammary tumor development (reviewed in 
Llovera et al., 2000a; Clevenger et al., 2003) and acts as a 
mitogen on several human breast cancer lines (Biswas et al., 
1987; Fuh and Vonderhaar, 1995; Ginsburg et al., 1995; Llovera et 
al., 2000b; Acosta et al., 2003; Schroeder et al., 2003). 
Epidemiological studies suggest a role for PRL in human breast 
cancer promotion and growth (Holtkamp et al., 1984; Bhatavdekar 
et al., 1990; Hankinson et al., 1999). However, anticancer 
therapies designed to block expression and secretion of pituitary 
lactogenic hormones (PRL and growth hormone) had little effect on 
the course of the disease (Anderson et al., 1993). One hypothesis 
that could account for this observation is a local expression of 
PRL acting through an autocrine/paracrine loop within the human 
breast (Clevenger et al., 1995; Ben-Jonathan et al., 2002; 
Clevenger et al., 2003). 
In addition to the pituitary gland, synthesis of PRL mRNA has 
been observed in T lymphocytes and decidualized endometrium 
(DiMattia et al., 1988; Gellersen et al., 1989; Pellegrini et 
al., 1992). Moreover, PRL mRNAs have also been detected in human 
mammary tissues (Fields et al., 1993; Clevenger et al., 1995; 
Reynolds et al., 1997). Expression of the PRL gene was observed 
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in both normal and neoplastic human breast tissue (Shaw-Bruha et 
al., 1997) and in human mammary cell lines derived from breast 
epithelium carcinoma (Clevenger et al., 1995; Ginsburg and 
Vonderhaar, 1995; Shaw-Bruha et al., 1997). The observation that 
hPRL antagonists blocked cultured mammary tumor cell growth 
further supports the existence of an autocrine/paracrine loop 
(Fuh and Wells, 1995; Ginsburg and Vonderhaar, 1995; Chen et al., 
2002). 
In pituitary, the hPRL mRNA starts with exon 1b at the 
pituitary start site and transcription is controlled by the 
pituitary promoter, extending to possibly 5.8 kb of upstream 
region (Truong et al, 1984). The pituitary promoter contains many 
binding sites for the pituitary-specific transcription factor 
Pit-1 and several binding sites for ubiquitous transcription 
factors (Van de Weerdt et al., 2000), the most prominent being 
the estrogen receptor. Recently, AP-1 was found to be involved in 
the control of the human pituitary promoter in response to MAPK 
ERKs activation (Caccavelli et al., 1998; Manfroid et al., 2001). 
Pit-1 independent non-pituitary hPRL gene transcription was 
reported in lymphocytes and endometrial cells (Gellersen et al., 
1994). Transcription of hPRL mRNA in lymphocytes and decidua is 
driven by an alternative, decidual/lymphoid promoter. A different 
start site is used, located 5.8 kb upstream from the pituitary 
start site, and the spliced RNA contains an additional exon (exon 
1a) (DiMattia et al., 1990). Thus, the 5'-UTR sequence in 
decidual/lymphoid cells is about 150 nucleotides longer than the 
pituitary 5’-UTR and both proteins are identical (Gellersen et 
al., 1994). Blood cell and endometrial hPRL expression was shown 
to be controlled by cAMP or cAMP and progesterone respectively 
(Gellersen et al., 1994; Telgmann et al., 1997; Pohnke et al., 
1999; Reem et al., 1999; Gerlo et al., 2003), the latter 
involving transcription factors of the Ets family (Brar et al., 
2002). Few studies are available concerning the promoter used in 
mammary cells and they give conflicting results. 
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Decidual/lymphoid type PRL transcripts were detected in some, but 
not all mammary tissues and cells (Shaw-Bruha et al., 1997), 
while a study performed in goat and sheep showed that the size of 
the mammary gland mRNA is similar to the pituitary hPRL mRNA (Le 
Provost et al., 1994). 
Here, we present an extensive study of the expression of the 
hPRL gene in the luminal epithelial mammary tumor cell line SK-
BR-3. Interestingly, our data argue for the use of the pituitary 
promoter, and not the decidual/lymphoid promoter, in these non-
pituitary cells, although no Pit-1 mRNA was detected. Both the 
transfected and the endogenous pituitary promoter are activated 
by epidermal growth factor (EGF) and exogenous Pit-1. EGF-
stimulation involves a PI3K/JNK pathway leading to binding of a 
c-jun/c-fos complex to an AP-1 site in the hPRL proximal 
pituitary promoter. 
 
MATERIALS AND METHODS 
 
Reagents 
EGF, SB203580 and Tyrphostin AG1478 were purchased at Sigma 
Chemical Co (St. Louis, MO). Bisindolylmaleimide, Wortmannin and 
N-acetyl-S-farnesyl-L-cysteine were provided by ICN 
Pharmaceuticals Inc. (Costa Mesa, CA). 
Specific anti- c-jun, -JunB, JunD, -c-fos, -FosB, -Fra-1 
antibodies are commercialized by Santa Cruz Biotechnology (Santa 
Cruz, CA). Monoclonal anti-Oct-1 (Lai and Herr, 1992) was a kind 
gift from W. Herr (Cold Spring Harbor, NJ). 
Rabbit polyclonal antibodies were obtained (Eurogentec, 
Seraing, Belgium) using bacterially expressed and purified hPRL 
16 kDa fragment (Struman et al., 1999) and shown to recognize the 
23 kDa hPRL. These and monoclonal anti-phospho-JNK (Santa Cruz 
Biotechnology, Santa Cruz, CA) were used for immunofluorescence 
staining analysis. Bacterially expressed and purified 23 kDa hPRL 
was obtained as described (Paris et al., 1990). 
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Cell culture 
Human SK-BR-3, derived from a breast adenocarcinoma (American 
Type Culture Collection), and lymphoid Jurkat cells were 
propagated in RPMI, HeLa cells (human cervix adenocarcinoma) in 
DMEM respectively containing 10% heat-inactivated fetal bovine 
serum and 1% penicillin/streptomycin (Gibco-BRL, Grand Island, 
NY). Human pituitary GX cells (Chomczynski et al., 1993), kindly 
provided by Dr. Frohman (Los Angeles, CA), were grown in MEM 
containing 10% horse serum. Growth conditions for rat pituitary 
GH3B6 cells were previously described (Caccavelli et al., 1998). 
 
Plasmids and oligonucleotides 
3474P-Luc, 1750P-Luc, 740P-Luc, 250P-Luc, 164P-Luc, 40P-Luc 
contain successive 5' deletions of the hPRL pituitary promoter 
driving the luciferase reporter gene. 3474P-Luc was obtained by 
insertion of the SstI/BglII fragment from 3474PRLCAT (Peers et 
al., 1990) into the corresponding sites of 250P-Luc (Poncelet et 
al., 1996). 1750P-Luc and 740P-Luc were obtained from 3474P-Luc 
by excising respectively the AflII/SstI and HindIII/SstI 
fragments followed by Klenow fill-in and religation. 3474P1,Pit-
1m-Luc and 3474P1,AP1m-Luc were obtained by joining the SstI/BsmI 
fragment from 3474P-Luc to a BsmI/BglII fragment (-64/+14) 
obtained by PCR respectively from 164P1,Pit-1m-Luc or 164P1,AP1m-
Luc (Caccavelli et al., 1998) using the appropriate primers and 
inserting them into the SstI/BglII digested pXP2 empty vector. 
164P-Luc and 40P-Luc and the expression plasmid for human Pit-1 
(pcDNA3-hPit-1) were previously described (Caccavelli et al., 
1998). The 1a1878PRL-Luc constructs contain the lymphoid/decidual 
promoter (Berwaer et al., 1994) driving the luciferase gene. 
RT-PCR and PCR were performed using the following primers in 
the hPRL mRNA (the positions are given relative to the ATG in the 
decidual hPRL cDNA sequence (Gellersen et al., 1989)): for1a 
(positions -132/-105 in exon 1a), for1b (positions –52/-27 in 
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exon 1b), for3 (positions 276/299 in exon 3), for4 (positions 
340/365 in exon 4) for reverse primers, and rev2 (positions 
118/142 in exon 2), rev5 (positions 496/525 in exon 5) as reverse 
primers. Primers for3, for4 and rev5 allow amplification of rat 
and human hPRL cDNA. 
Primers designed in hPit-1 cDNA are PITfor (positions -13/+9 
in exon 1) and PITrev (positions 353/378 in exon 2), positions 











Oligonucleotides P1, AP-1, P1(Pit-1)m, P1(AP-1)m, Oct-1 and 
NF-Y were described (34). 
 
RT-PCR and PCR 
Poly-A RNAs were prepared using the QuickPrepTM Micro mRNA 
purification kit (Amersham Pharmacia Biotech Inc, NJ). RT-PCR 
reactions were performed with the Titan One Tube RT-PCR kit 
(Roche Diagnostics Corporation, IN) with 250 ng of mRNA as 
recommended by the manufacturer. Briefly, cDNA synthesis was 
carried out at 55° C for 30 min, followed by 40 PCR cycles (94°C 
45 sec, 64°C 30 sec, 68° 30 sec). Where indicated, a second PCR 
was performed as follows: sample (from the first RT-PCR) dilution 
1/500, 200 µM dNTP, 10 pmoles primers, 0.25 U Taq polymerase Gold 
(Perkin Elmer, Life Sciences, Boston, MA), 1x buffer, 1.5 mM 
MgCl2 in 50 µl. An initial 7 min step at 95°C (DNA denaturation 
and Gold Taq polymerase activation) followed by 35 cycles (94°C 
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45 sec, 64°C 30 sec and 68°C 30 sec). 10 µl were loaded on a 3% 
agarose ethidium bromide stained gel and revealed with UV light. 
For semi-quantitative RT-PCR, the linear range of the PCR 
amplification reaction was determined for control and EGF-treated 
cell samples using 0.1 ng mRNA and the parameters detailed above, 
testing the amount of amplified product every 3 cycles. A similar 
approach was used for α-tubulin. The reactions were calibrated 
using α-tubulin amplifications and the results for hPRL after 
equivalent numbers of cycles are shown. Quantification of the 
specific bands was performed using the NIH Image software. 
 
Transfections 
3.105 SK-BR-3 cells were plated in 6-well dishes the day 
before transfection. Transient transfections were performed using 
Lipofectamine PlusTM (Gibco-BRL, Grand Island, NY) with 2 µg DNA 
as already described (Manfroid et al., 2001). The day following 
transfection, cells were treated with 50ng/ml EGF, or with 
different inhibitors as indicated, diluted in the culture medium. 
18 hrs later, the cells were harvested and the luciferase 
activities in cellular extracts were determined as described 
(Manfroid et al., 2001). The luciferase activities were 
normalized relative to the amount of total protein in the 
extracts, as measured using a standard colorimetric Bradford 
assay. Each transfection was performed in triplicate at least 
twice. The mean relative light units ± S.D. are shown in Fig.2B 
and 2D. Fold inductions were calculated as the ratio between 
promoter activity in treated cells/ promoter activity in 
untreated cells. S.D. values were obtained accordingly. 
 
EMSAs and Western blots 
Nuclear protein extracts were prepared as previously described 
(34). For whole cell extracts, cells were lysed in 400 mM KCl, 
20% glycerol, 20 mM Hepes pH=7.8, 2 mM DTT, centrifuged for 30 
min at 14000 rpm and the supernatant collected. EMSAs and Western 
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For immunofluorescence staining analysis, 106 cells were 
seeded in P30 dishes in culture medium. After 18 h, the medium 
was replaced by medium containing 1% serum, then cells were grown 
for further 24 h. For phospho-JNK analysis, cells were submitted 
for 30 min to several treatments as indicated and fixed in 4% 
paraformaldehyde. Cells were then stained with anti-phospho-JNK 
followed by Texas red-coupled anti-mouse secondary antibody 
(Amersham/Pharmacia Biotech Inc, NJ). For hPRL detection, 106 
cells were either mock transfected or transfected with 2 µg 
pcDNA3-hPit-1 (Manfroid et al., 2001) using Lipofectamine PlusTM. 
24 h after transfection, cells were fixed and stained with anti-
hPRL 16K. Fluorescein isothiocyanate (FITC)-coupled anti-rabbit 
was used as secondary antibody (Amersham Pharmacia Biotech Inc, 
NJ). Slides were examined using an Olympus BX60 microscope 





Human SK-BR-3 mammary cells synthesize hPRL mRNA and protein 
The presence of hPRL protein in SK-BR-3 whole-cell extracts 
was assessed by Western blot assay (Fig. 1A). Extracts from PRL-
expressing lymphoid Jurkat cells and from HeLa cells were used as 
positive and negative controls, respectively. A clear hPRL signal 
of apparent molecular weight 23-26kDa was detected in Jurkat and 
SK-BR-3 extracts. No hPRL was detected in HeLa cell extracts, as 
expected. When defined amounts (200 and 500 ng) of bacterially 
expressed and purified hPRL protein were used as a standard, 
comparison of the signal intensities suggests that the amount of 
hPRL in 60 µg of SK-BR-3 extracts is much lower than 200 ng. 
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To ensure that hPRL is indeed synthesized in SK-BR-3 cells, 
the presence of hPRL mRNAs in mammary SK-BR-3 cells was assessed 
by RT-PCR using specific primers located in exons 3, 4 and 5 (see 
fig 1B). As a positive control, two pituitary cell lines were 
used: human GX and rat GH3B6 cells. A 250 bp fragment was 
obtained with the primer pair for3/rev5 from GX, GH3B6 and SK-BR-
3 cells (Fig. 1C). To confirm the identity of this fragment, a 
second PCR reaction was performed on the RT-PCR samples with the 
internal forward primer for4 and rev5. A 185 bp fragment was 
obtained in each case (Fig. 1C). The PCR product obtained from 
SK-BR-3 cells was cloned for sequencing and was completely 
identical to the expected hPRL sequence (data not shown). No hPRL 
messenger was detected in HeLa cells, a human cervix cell line 
that does not express PRL. The α-tubulin mRNA was used to control 
the RT-PCR reactions. 
In human, two distinct hPRL gene promoters are used depending 
on the cell type: the pituitary promoter and the 
lymphocyte/decidual promoter. The mRNA transcribed from the 
lymphoid/decidual promoter is characterized by a 150 nucleotides 
extension in the 5'-untranslated region relative to the pituitary 
type transcript (Fig. 1B). To determine which type of hPRL mRNA 
is present in SK-BR-3 cells, RT-PCR reactions were performed 
using forward primers corresponding to the lymphoid/decidual exon 
1a (for1a) or to the common exon 1b (for1b) with a reverse primer 
localized in exon 2 (rev2) (Fig. 1D). Control reactions were 
performed on RNA from lymphoid Jurkat and pituitary GX cells. 
Both primer pairs generated the anticipated fragments in Jurkat 
cells, as expected for the presence of lymphoid type RNA, while 
hPRL mRNAs were amplified only with primers for1b/rev2 in 
pituitary GX cells, as expected from pituitary-type mRNA. In SK-
BR-3 cells, mRNA containing exon 1b, but not exon 1a was 
detected, suggesting the use of the pituitary promoter in these 
mammary tumor cells. No RT-PCR fragment was obtained from the 
HeLa cell RNA (negative control). 
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The hPRL pituitary promoter is transcriptionally active in SK-
BR-3 cells 
To test for the transcriptional activity of the hPRL gene 
promoters, transfections were performed in SK-BR-3 cells using 
reporter constructs containing the lymphoid/decidual promoter 
(1a1878PRL-Luc) or successive 5'-deletions of the pituitary hPRL 
control region: 3474P-Luc, 1750P-Luc, 740P-Luc, 250P-Luc, 164P-
Luc and 40P-Luc (Fig. 2A). Significant basal transcriptional 
activity was observed in SK-BR-3 with all promoter constructs 
when compared with the minimal promoter construct 40P-Luc in this 
transient assay (Fig. 2B). Successive 5'-deletions of the 
pituitary hPRL promoter resulted in a gradual decrease of 
reporter gene expression, demonstrating the presence of cis 
elements necessary for full activity along the entire upstream 
regulatory region. 
In pituitary cells, the cell-specific transcription factor 
Pit-1 is one of the main activators of the hPRL gene pituitary 
promoter. To assess the presence of Pit-1 in SK-BR-3 cells, we 
performed RT-PCR experiments on mRNA from these cells using 
primers specific for human Pit-1. A specific fragment 
corresponding to a normally spliced Pit-1 cDNA was only observed 
in pituitary GX cells, used as a positive control, whereas no 
signal was obtained in HeLa and SK-BR-3 cells (Fig. 2C). When SK-
BR-3 cells were cotransfected with the 3474P-Luc construct and an 
expression vector for human Pit-1, a strong activation was 
observed as compared to the control with an empty expression 
vector (Fig. 2D). 
The effect of hPit-1 expression on the endogenous hPRL gene 
was also examined (Fig. 2E). Immunostaining of hPRL is 
significantly stronger in Pit-1 transfected SK-BR-3 cells as 
compared to mock-transfected cells, showing for the first time 
that the endogenous hPRL gene is able to respond to Pit-1 in non-
pituitary human cells. 
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These results not only show that Pit-1 is able to activate 
both transfected hPRL pituitary promoter and endogenous hPRL in 
mammary SK-BR-3 cells, but also that a significant activity of 
this promoter is observed in the absence of the pituitary factor 
Pit-1. The transfected lymphoid/decidual promoter displays a 
similar basal activity. 
 
EGF activates the hPRL pituitary promoter in SK-BR-3 cells 
SK-BR-3 cells are known to highly express some members of the 
EGF/Neu receptor family (EGFR/ErbB1, ErbB2, ErbB3 and ErbB4), 
especially erbB1 and 2. Therefore, we tested the hPRL promoters 
for their ability to respond to EGF in these cells. Used as a 
negative control, the 40P-Luc construct containing only a TATA-
box displayed a weak (2-fold) stimulation, probably reflecting a 
non-specific activation of the basal transcription machinery by 
EGF (Fig. 3A). Compared to 40P-Luc, the 3474P-Luc pituitary 
promoter construct was significantly stimulated by EGF treatment. 
In contrast, the lymphoid/decidual promoter (1a1878PRL-Luc) did 
not respond to EGF, suggesting that EGF signaling selectively 
targets the pituitary promoter. When the 5’-deleted pituitary 
promoter constructs were tested, EGF stimulation was clearly 
maintained, even with the shortest 164P-Luc construct, suggesting 
that EGF stimulation in SK-BR-3 cells acts on the 164 most 
proximal base pairs of the hPRL pituitary promoter. 
 
The endogenous pituitary-type hPRL mRNA is up-regulated by EGF 
in SK-BR-3 cells 
EGF regulation of the endogenous hPRL gene in SK-BR-3 cells 
was monitored by semi-quantitative RT-PCR. After 25 amplification 
cycles (in the linear part of the PCR reaction), the signal 
obtained from EGF-treated SK-BR-3 was clearly stronger than from 
control cells (Fig. 3B, left panel). Thus, the amount of hPRL 
mRNA was significantly increased in SK-BR-3 cells upon EGF 
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treatment as compared with control cells. In contrast, the 
constitutive α-tubulin transcription was not affected. 
When PCR reactions were performed using the forward primers 
for1a or for1b and the reverse primer rev2, an enhanced signal 
(at least 2-3 fold) upon EGF treatment was only observed with 
for1b, corresponding to pituitary-type hPRL mRNA. 
 
EGF induces the binding of an AP-1 complex within the proximal 
hPRL promoter 
Deletion analysis of the hPRL promoter revealed that the EGF 
activated pathway targets mainly the –164/+1 most proximal 
regulatory region. This region contains two Pit-1 binding sites, 
the “sequence A” binding ubiquitous factors and an AP-1 binding 
element located upstream from the proximal Pit-1 binding site in 
the P1 region (Fig. 4A). This AP-1 site is critical for basal and 
okadaic acid (a protein phosphatase inhibitor) regulated 
transcription in pituitary GH3B6 cells (Caccavelli et al., 1998; 
Manfroid et al., 2001). We assessed the role of AP-1, a potential 
EGF target, in the EGF-induction of the hPRL promoter in SK-BR-3 
cells. Mutation of the AP-1 binding site in 164P-Luc clearly 
decreased EGF-stimulation of the 164hPRL promoter in SK-BR-3, 
close to that of the minimal 40P-Luc construct (Fig. 4B). 
Mutation of the proximal Pit-1 binding site in 164P-Luc resulted 
in a two-fold decrease of the basal level, but the EGF 
stimulation was hardly affected (Fig. 4B and 4C). 
Gel retardation assays were performed to compare DNA binding 
factors in SK-BR-3 cells in absence or presence of EGF. The 
binding properties of sequence A or P2 were not influenced upon 
EGF treatment, consistent with a role in the EGF response for P1 
alone (Fig. 5A, lanes 15 and 18). Using a probe encompassing the 
P1 region (containing the AP-1 site and the proximal Pit-1 site), 
a strongly enhanced complex was observed upon EGF treatment (lane 
3). An additional, more slowly migrating complex was also 
observed, which was not consistently induced by EGF (compare lane 
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3 and 21, and see below). The faster migrating complex was not 
obtained when the P1 sequence mutated in the AP-1 site was used 
(lane 12). In contrast, mutation of the Pit-1 binding site did 
not affect formation of this complex (lane 9). A similar complex 
was observed on a consensus AP-1 response element in SK-BR-3 
cells treated with EGF (lane 6). Competition experiments (Fig. 
5B) revealed that an excess of cold P1 oligonucleotide, P1 
mutated in the Pit-1 site or a consensus AP-1 site abolished 
formation of this complex, while the P1 probe mutated in the AP-1 
site, a consensus Oct-1 site or the unrelated NF-Y binding site 
had no effect. Taken together, these results strongly suggest 
that EGF induces the binding of an AP-1 complex to P1. Using 
specific antibodies, we show that this complex is composed of the 
proto-oncogenes c-fos and c-jun, as demonstrated by the 
supershift and the abrogation of the shift induced, respectively 
by c-fos and c-jun antibodies (lanes 12, 14). The other fos and 
jun family members FosB, JunB and JunD were not detected in the 
AP-1 complex (lanes 13, 15, 16). The slower complex observed on 
P1 was also observed with the P2 probe, containing a Pit-1 
binding site. Mutation of the Pit-1 site abolished the formation 
of this complex and competition with an excess of cold P2 or a 
consensus site for Oct-1 allowed us to identify this complex as 
Oct-1 (lane 8). The supershift observed with specific Oct-1 
antibodies confirmed this conclusion (lane 10). 
Western blot analysis of nuclear proteins in SK-BR-3 revealed 
that the c-fos and c-jun protein levels dramatically increase 
upon EGF treatment, probably accounting for the increased binding 
of these factors to AP-1 elements (Fig. 5C). Moreover, EGF 
treatment did not affect the other AP-1 proteins JunB, JunD, FosB 
and Fra-1, consistent with the results obtained in gel 
retardation experiments. Fra-2 could not be detected (not shown). 
 
EGF stimulation of hPRL involves activation of JNK by PI3K 
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Activation of the EGF receptor triggers several different 
signal transduction pathways, depending on the cell type and the 
precise physiological condition of the cells. To gain some 
insight into the mechanism of hPRL stimulation by EGF, specific 
inhibitors were used.  
SK-BR-3 cells were transfected with the 3474-PRL pituitary 
promoter construct and its activation by EGF was determined. As 
expected, the three-fold stimulation of hPRL promoter activity 
was completely abolished when the specific inhibitor (AG1478) of 
the EGF receptor was added (Fig. 6). Inhibition of ras (AFC) or 
the protein kinases MEK1/2 (PD98059), p38 (SB203580) and protein 
kinase C (Bis) only marginally affected the hPRL promoter 
activity in the presence of EGF. In contrast, inhibition of the 
PI3-Kinase resulted in a significant decrease of EGF-stimulated 
hPRL activity. None of these drugs significantly affected the 
hPRL basal level transcription. Thus, PI3K is clearly involved in 
EGF-stimulation of the hPRL pituitary promoter in SK-BR-3 cells. 
A possible target for the PI3K pathway is the c-Jun NH2-
terminal kinase, which is also the main kinase known to control 
c-jun and AP-1 activity (Hibi et al., 1993). To test whether JNK 
is involved in hPRL activation, we performed immunofluorescence 
staining using an anti-phospho-JNK antibody (Fig. 7). A strong 
staining was obtained with EGF-treated cells, similar to that in 
UV-treated cells that were used as positive control, suggesting 
that EGF is able to stimulate JNK in SK-BR-3. More importantly, 
addition of the PI3K inhibitor Wortmannin to the EGF-treated 
cells reduced phospho-JNK staining to the level obtained with 
Wortmannin alone, or in untreated control cells. These results 
indicate that JNK is likely involved in EGF and PI3K activation 
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The previously described expression of hPRL in several mammary 
cell lines (Fields et al., 1993; Clevenger et al., 1995; Ginsburg 
and Vonderhaar, 1995; Shaw-Bruha et al., 1997) is particularly 
interesting, as this tissue also is the major target site for PRL 
in mammals. Here, we describe for the first time the molecular 
mechanisms involved in transcription of the hPRL gene in SK-BR-3 
mammary tumor cells and we show that EGF and hPit-1 stimulate 
transcription of both the endogenous hPRL gene and a transfected 
hPRL promoter. 
 
The pituitary promoter drives hPRL expression in SK-BR-3 cells 
Two alternative transcriptional start sites were described for 
the hPRL gene. One is used in the pituitary (exon1b); the other 
in various extra-pituitary expression sites that produce a mRNA 
extended in its 5’-untranslated region (exon1a). Using RT-PCR, 
the presence of hPRL mRNA containing exon1a was observed in 
normal as well as neoplastic human mammary tissues and in tumor 
cell lines, while mRNA containing only exon1b was detected in 
other cells (Shaw-Bruha et al., 1997). Here, we confirm the 
synthesis of hPRL both at the protein and the mRNA level in SK-
BR-3 cells, a highly tumorigenic cell line. The presence of 
exon1a was not detected in SK-BR-3 mRNA by RT-PCR, indicating 
that the hPRL mRNA is not of the lymphoid/decidual type and thus 
that a different promoter is used in these cells. Transient 
expression experiments showed that the pituitary promoter is 
indeed functional in SK-BR-3 cells and drives significant 
expression of the luciferase reporter gene as compared to the 
40P-Luc construct containing only the TATA-box. The expression 
pattern observed for the 5’-deletion constructs is similar to 
that obtained in pituitary cells (Van de Weerdt et al., 2000). 
The observed basal activity of the decidual/lymphoid promoter was 
previously shown in a number of different cell lines (Gaasenbeek 
et al., 1999). One of the main activators of the pituitary 
promoter is the transcription factor Pit-1. No mRNA coding for 
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human (h)Pit-1 was detected by RT-PCR in SK-BR-3 cells, however 
the transfected pituitary promoter is clearly induced by 
expression of hPit-1, while the transfected lymphoid/decidual 
promoter is not (Gellersen et al., 1994 and Fig. 3). EGF 
treatment also induces specifically the transfected pituitary 
promoter. Interestingly, expression of hPit-1 and treatment with 
EGF also clearly enhance expression of the endogenous hPRL gene. 
The fact that the transfected and the endogenous hPRL pituitary 
promoters are both induced by EGF and hPit-1 argues for the use 
of the hPRL pituitary promoter in SK-BR-3 cells. Although we 
cannot exclude the presence of a third, not yet identified, 
promoter in the hPRL gene as we have not formally determined the 
transcription start site, our results strongly indicate that the 
hPRL pituitary promoter is used in SK-BR-3 cells. In addition, 
these cells are the first non-pituitary human cells where Pit-1 
and EGF stimulation of the endogenous hPRL gene was observed. 
 
HPRL promoter activity in SK-BR-3 cells does not require Pit-
1, possibly replaced by the POU-domain factor Oct-1.  
Previously, pituitary-type transcription of the hPRL gene 
(originating at exon 1b) was observed in the uterine cell line 
SK-UT-1B-20 (Gellersen et al., 1995). However, similar to hPRL 
expression in lymphocytes, (Gellersen et al., 1994), the 
expression was mainly controlled by a region located in the 
decidual/lymphoid promoter, and significant activity of the 
transfected pituitary proximal promoter was only observed when 
exogenous Pit-1 was expressed (Gellersen et al., 1994; 1995). In 
contrast, in SK-BR-3 cells, an expression pattern of the 5'-
deletion constructs similar to that observed in pituitary cells 
was obtained in the absence of hPit-1. A 7-fold higher activity 
relative to 40P-Luc is obtained even with the shortest promoter 
construct tested, the 164P-Luc. Addition of further upstream 
sequences resulted in a gradual increase of transcriptional 
activity, suggesting that multiple activating sites are present 
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in this region. Pit-1 binding sites are obvious candidates for 
such a regulation. Mutation of only the most proximal Pit-1 site 
results in a clear decrease of expression from the 164P-Luc 
construct. We show in gel retardation experiments that this site 
is able to bind in vitro the ubiquitous Oct-1, a member of the 
POU homeobox protein family also containing Pit-1. Binding to the 
P1 site by Oct-1 was also previously shown in pituitary cells 
(Caccavelli et al., 1998) and synergistic activation by Oct-1 and 
Pit-1 of the rat PRL promoter was reported (Voss et al., 1991). 
Thus, it is likely that Oct-1 substitutes for Pit-1 in basal 
expression of the hPRL promoter in SK-BR-3 cells. Mutation of the 
adjacent AP-1 site also decreased basal expression suggesting 
that AP-1 contributes to promoter activity, similar to what was 
shown before in rat pituitary cells (Caccavelli et al., 1998; 
Manfroid et al., 2001). 
 
EGF stimulates the hPRL pituitary promoter through the 
PI3K/JNK/AP-1 pathway 
EGF is an important regulator of mammary gland development as 
well as breast tumor growth (Kim and Muller, 1999). In SK-BR-3 
cells, EGF stimulation of 164P-Luc involves the AP-1 site 
adjacent to the most proximal Pit-1 binding sequence. Although 
both sites contribute to the basal hPRL promoter activity (see 
above), the Pit (Oct )-1 site is not required for EGF regulation.  
We previously showed that the enhanced binding of AP-1 
complexes in pituitary cells upon stimulation of the MEK/ERK 
pathway results from an increase in cellular amounts of c-fos and 
junD (Caccavelli et al., 1998; Manfroid et al., 2001). In SK-BR-3 
cells, the amount of AP-1 complexes is also increased upon EGF 
treatment, but the complex formed is a c-fos/c-jun dimer. EGF 
binding to its tyrosine kinase receptor EGFR (ErbB1) leads to 
receptor heterodimerization with ErbB2, phosphorylation of both 
receptors and activation of downstream pathways such as 
Ras/Raf/MEKs/ERKs, Ras/MEKKs/MKKs/JNK, PI3K/AKT or p70S6K (Kim 
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and Muller, 1999). To understand the molecular events leading to 
the hPRL promoter stimulation by EGF, we used specific kinase 
inhibitors. Other than blocking the EGFR itself, only inhibition 
of PI3K led to a decrease of EGF stimulation of the hPRL 
pituitary promoter. We further show that EGF activates JNK in a 
PI3K-dependent way. Thus, our results suggest that EGF 
stimulation of the hPRL gene in SK-BR-3 cells involves the 
EGFR/PI3K/JNK/AP-1 pathway. 
PRL expression has been observed in normal and tumoral breast 
tissues as well as in mammary cell lines (Fields et al., 1993; 
Clevenger et al., 1995; Ginsburg and Vonderhaar, 1995; Shaw-Bruha 
et al., 1997). In humans, a role in cancer initiation and 
progression has been proposed (reviewed in Clevenger et al., 
2003). PRL stimulates human breast cancer cell proliferation (Fuh 
and Wells, 1995; Llovera et al., 2000; Acosta et al., 2003; 
Schroeder et al., 2003), particularly PRL stimulates SK-BR-3 cell 
growth, whereas PRL antagonists block their proliferation (Fuh 
and Wells, 1995). The existence of an autocrine/paracrine 
mitogenic loop following local synthesis of PRL in mammary tissue 
itself was proposed (reviewed in Ben-Jonathan et al., 2002). As 
observed in 25-50% of human breast cancers (Slamon et al., 1987; 
Bacus et al., 1994), SK-BR-3 cells express high levels of EGFR 
(ErbB1) and of constitutively activated ErbB2. Recently, Yamauchi 
et al. (Yamauchi et al., 2000) demonstrated that PRL secreted by 
SK-BR-3 cells is able to activate ErbB2 and the MAPK pathway via 
autocrine binding to PRLR followed by Jak2 activation. The 
stimulation of hPRL synthesis by EGFR/ErbB2 with the subsequent 
activation of PI3K/JNK/AP-1 offers a potential mechanism for 
autostimulation of mammary tumor cells such as SK-BR-3. 
Taken together, our results provide first insights into the 
control of local expression of hPRL in mammary cells and 
contribute to the understanding of the regulatory network 
underlying hPRL expression in extra-pituitary cells. 
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FIGURE LEGENDS: 
 
FIG. 1. HPRL is expressed in SK-BR-3 cells from a mRNA containing 
exon 1b, but not the lymphoid/decidual specific exon 1a. A. 
Western blot showing expression of hPRL protein in whole cell 
extracts (60 µg) from human mammary SK-BR-3 cells. Equal amounts 
of extracts from HeLa and Jurkat cells were used as negative and 
positive control, respectively. For comparison, the indicated 
amounts of bacterially expressed and purified hPRL were also 
loaded. B. Schematic representation of the pituitary-type and the 
lymphoid/decidual-type hPRL mRNA and localization of the primers 
used in the RT-PCR experiments. C. RT-PCR performed with the 
primers designed in exon 3, 4 and 5 of the hPRL gene. Primers 
inside the α-tubuline gene were used to control the PCR 
reactions. HeLa cells are the negative control and Jurkat and GX 
were used as a positive control. D. Determination of the exons 
(1a or 1b) present in the hPRL mRNA in SK-BR-3 cells. Jurkat and 
GX mRNAs were used as controls for exon1a and 1b respectively. 
 
FIG. 2. Transcription of the hPRL gene in SK-BR-3 cells is driven 
by the pituitary promoter in the absence of the pituitary factor 
Pit-1. A. Illustration of the pituitary and the upstream 
lymphoid/decidual promoters. The promoter constructs used in 
transfection experiments are indicated. B. Promoter activity 
measured in transient expression experiments performed with the 
pituitary and decidual/lymphoid promoter constructs. The 
activities of the 5'-deletion constructs of the pituitary 
promoter are included. The minimal construct 40P-Luc contains 
only the TATA box of the pituitary promoter. Activities are 
normalized to the protein concentration of the extracts and shown 
as the mean relative light units ± S.D. from triplicate 
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experiments performed at least twice C. RT-PCR reactions 
performed with primers within the hPit-1 gene. Pituitary GX cells 
were used as positive control. D. Transient expression 
experiments showing the pituitary promoter activity in absence 
and presence of transfected hPit-1 expression vector in SK-BR-3 
cells. E. Immunostaining with anti-hPRL antibody on SK-BR-3 cells 
transfected with hPit-1 expression vector or mock-transfected 
control. The cells were observed at a 100- (left) or 300-fold 
(right) magnification. 
 
FIG. 3. In SK-BR-3 cells, EGF stimulates both the transfected and 
the endogenous hPRL pituitary promoter. A. SK-BR-3 cells were 
transfected with the indicated hPRL lymphoid/decidual or 
pituitary promoter constructs and treated or not with 50ng/ml of 
EGF. The results are shown as fold induction by EGF relative to 
untreated cells ±S.D. from triplicate experiments performed at 
least twice is shown. B. RT-PCR reactions were performed on mRNA 
from control and EGF-treated SK-BR-3 cells. Calibration was 
performed by amplifying the α-tubulin gene (left panel). Exon1a- 
or exon1b-specific reactions are also shown (right panel). Refer 
to Fig. 1B for the nomenclature and positions of the primers used 
in the PCR reactions. 
 
FIG. 4. Mutation of the AP-1 binding site in the proximal hPRL 
pituitary promoter abolishes EGF stimulation, while AP-1 and Pit-
1 sites both govern basal transcription. A. Detailed 
representation of the 164P-Luc construct containing the proximal 
pituitary promoter of the hPRL gene. Regions corresponding to 
binding sites P2, A and P1 are shown as well as the specific AP-1 
and Pit-1 recognition sites. B. The 164P-Luc construct and its 
mutant versions in the AP-1 or Pit-1 site were transfected into 
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SK-BR-3 cells and the transcriptional activity in the presence of 
50ng/ml was determined relative to untreated controls. C. The 
basal activity in the absence of EGF is shown for each of the 
constructs. 
 
FIG. 5. EGF induces the binding of a c-jun/c-fos complex to the 
AP-1 binding site of the pituitary proximal hPRL promoter. A. Gel 
retardation experiments performed with nuclear protein from 
untreated control and EGF-treated SK-BR-3 extracts. The cells 
were treated the day after seeding with 50 ng/ml EGF for 18h. 
Probes corresponding to the P1, a consensus AP-1, P1(Pitm), 
P1(AP1m), sequence “A” and P2 were used, as indicated. The probes 
were incubated alone or in the presence of untreated and treated 
cell extract. The position of the AP-1 complex is indicated. The 
slower migrating complex (arrow) is not detected upon EGF 
treatment in a separate independent experiment (probe P1, right 
panel). B. (Left panel) Competition experiments using the P1 
probe with nuclear extracts from EGF-treated SK-BR-3 cells and a 
200-fold excess of the indicated cold oligonucleotides. (Right 
panel) Identification of the EGF-induced complex using specific 
antibodies as indicated. The c-fos antibody induces a supershift, 
while anti-c-jun prevents complex formation C. Analysis of the 
protein amounts of different members of the AP-1 protein family 
in nuclear extracts from SK-BR-3 cells treated with EGF as 
compared to control cells. 
 
FIG. 6. EGF activation of the hPRL pituitary promoter involves 
the PI3K. SK-BR-3 cells were transfected with 3474P-Luc and 
treated or not with EGF. In addition, solvent or inhibitors of 
the EGFR (AG1478: 1µM), Ras (AFC: 40µM), MEK (PD98059: 50µM), 
PI3K (Wortmannin – Wort: 1µM), p38 (SB203580: 10µM), PKC 
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(bisindolylmaleimide – bis: 2.5µM) protein kinases were added and 
fold induction relative to untreated cells is shown from 
triplicate experiments performed at least twice. The unshaded bar 
on the left represents control cells not treated with EGF or any 
of the inhibitors (fold-induction equal to 1 ± S.D.) 
 
FIG. 7. EGF stimulates JNK phosphorylation by PI3K. SK-BR-3 cells 
treated as indicated were immunostained with anti-phospho-JNK 
antibodies. UV-irradiation was used as positive control for JNK 
phosphorylation.  
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